Introduction
Signal transduction from the membrane to the nucleus upon ligand stimulation of a cytokine receptor is mediated primarily by specific tyrosine kinases, such as Janus kinases (JAKs), and latent cytoplasmic transcription factors, such as signal transducers and activators of transcription (STATs) (Ihle et al., 1995; Watanabe and Arai, 1996;  © Oxford University Press 5321 Darnell, 1997) . Four JAK family members are known in mammals, JAK1, JAK2, JAK3 and TYK2. JAK kinases have shared structural domains designated as JH segments 1-7. JH1 is the kinase domain located at the C-terminus and is preceded by the JH2 pseudokinase domain, which has been suggested to be an inhibitory domain regulating JAK2 kinase activity (Luo et al., 1997) . JAK proteins associate with cytokine receptors, and ligand stimulation of the cytokine receptor and activation of associated JAKs leads to phosphorylation of specific tyrosine residues on the receptor. This allows SH2-containing signaling proteins, including STATs, and adapter proteins to bind. JAK phosphorylation of STAT proteins induces STAT hetero-and homodimer formation and translocation to the nucleus, where the complexes bind to specific DNA response elements and activate transcription of genes. To date six members of the STAT family (STAT 1-4, 5A, 5B, 6) have been identified (Darnell, 1997; Leaman et al., 1996) .
The importance of the JAK-STAT pathway in cytokine signaling suggests a potential role in the pathogenesis of hematological malignancies (Watanabe and Arai, 1996) . Several lines of evidence support this hypothesis. First, constitutive activation of the JAK-STAT pathway has been demonstrated in HTLV-1-transformed T cells (Mignone et al., 1995; Xu et al., 1995) . Secondly, a single amino-acid mutation in the Drosophila melanogaster JAK (encoded by the Hopscotch locus) has been shown to cause leukemia-like hematopoietic defects (Luo et al., 1995 (Luo et al., , 1997 . Thirdly, the transforming oncoproteins v-abl, p210(BCR/ABL) and p190(BCR/ABL) induce tyrosine phosphorylation and DNA-binding activity of multiple specific STAT family members (Danial et al., 1995; Carlesso et al., 1996; Ilaria and Van Etten, 1996; Shuai et al., 1996) , and constitutively activated STATs have been found in cells from patients with chronic myelomonocytic leukemia (CML), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) (Gouilleux-Gruart et al., 1996; Chai et al., 1997; Frank et al., 1997) . Moreover, constitutive activation of the JAK-STAT pathway has been found in malignant cutaneous T-cell disease (mycosis fungoides, Sézary syndrome) Nielsen et al., 1997) . Finally, leukemic cells from patients with relapsed ALL have constitutively activated JAK2, and inhibition of JAK2 activity by a specific tyrosine kinase blocker (AG-490) selectively blocks leukemic cell growth in vitro and in vivo (Meydan et al., 1996) . But perhaps the most direct evidence for involvement of JAK family members in leukemogenesis has been the characterization of chromosomal translocations from leukemic cells involving the JAK2 kinase gene on 9p24 and the TEL gene on 12p13.
The TEL gene (also known as Ets-translocation variant gene 6, ETV-6) was initially cloned as the fusion partner of platelet-derived growth factor receptor β gene (PDGFβR) in CML with t(5;12) (q31;p13) (Golub et al., 1994) . TEL has subsequently been shown to be fused to several partner genes on different chromosomes including AML1(CBFA2) in t(12;21) (p13;q22) associated with childhood pre-B ALL (Golub et al., 1995) ; ABL in t(9;12) (q34;p13) in rare cases of childhood ALLs (Papadopolous et al., 1995) ; MN1 in t(12;22) (p13;q11) in AML (Buijs et al., 1995) ; and MDS/EVI1 in t(3;12) (q26;p13) associated with myeloproliferative disorders (Peeters et al., 1997a) . The TEL gene on 12p13 codes for a ubiquitously expressed nuclear protein which contains a C-terminal conserved DNA-binding domain of ETS transcription factors (Golub et al., 1994; Poirel et al., 1997) . TEL is one of a subset of the ETS family of transcription factors that contains a conserved N-terminal domain which has been variously referred to as the pointed (PNT) domain, based on homology to the Drosophila ETS-protein pointed, the N-terminal conserved domain (NCR), or the helixloop-helix domain, based on weak homology to the basic helix-loop-helix domain found in transcription factors such as myc and myo-D (Wasylyk et al., 1993) . The PNT domain was shown to be important for transcriptional activity despite the lack of DNA contact, but no other function was known prior to the cloning of the TEL/ PDGFRβ fusion gene (Rao et al., 1993) . Analysis of the TEL fusion proteins in the context of the PNT domain has provided evidence that this domain acts as a self association domain of functional importance. The PNT domain is essential for TEL/AML1-mediated repression of AML1-dependent transcription (Hiebert et al., 1996) . Furthermore, oligomerization by the PNT domain leads to constitutive activation of the ABL and PDGFRβ tyrosine kinase domains, which is necessary for cellular transformation (Carroll et al., 1996; Golub et al., 1996; Jousset et al., 1997) .
Three distinct TEL/JAK2 fusions have recently been cloned. The first is a fusion between TEL exon 5 and JAK2 exon 12 from a patient with atypical CML and a complex t(9;12;14) translocation ]; the second is a fusion of TEL exon 4 to JAK2 exon 17 in a patient with pre-B cell ALL and t(9;12) (p24;p13) ]; and the third is a fusion of TEL exon 5 to JAK2 exon 19 in a case of T-cell childhood ALL and t(9;12) (p24;p13) [TEL/JAK2 (5-19)] (Lachronique et al., 1997; Peeters et al., 1997b) .
By analogy with other TEL-tyrosine kinase fusion proteins (TEL/PDGFRβ, TEL/ABL) we hypothesized that the JAK2 tyrosine kinase was constitutively activated by oligomerization mediated by the TEL PNT domain, leading to transformation of hematopoietic cells (Carroll et al., 1996; Golub et al., 1996; Jousset et al., 1997) . The transforming properties of TEL/JAK2 fusion genes were tested in growth-factor-dependent, murine hematopoietic cell lines and in vivo by transplant of primary murine bone marrow infected with TEL/JAK2 retroviral expression vectors into lethally irradiated recipients. Our results show that all TEL/JAK2 fusion variants transform hematopoietic cells to factor-independent growth and that transformation is dependent on the presence of the TEL PNT domain as well as an active JAK2 kinase domain. TEL/JAK2 is localized to the cytoplasm of cells, and is a potent activator of STAT 5. In addition, the TEL/JAK2 variant associated 5322 with human T-ALL induces a rapidly fatal mixed myeloand T-cell lymphoproliferative disorder in mice reflecting, at least in part, the heterogeneity of the human leukemic phenotypes associated with TEL/JAK2 fusions.
Results
Human TEL fused to the kinase domain of murine Jak2 transforms hematopoietic cells to growthfactor independence Previous reports have demonstrated that upon ligandmediated dimerization, extracellular cytokine receptor domains (EGF, CD16) are able to induce phosphorylation and activation of a fused JAK2 tyrosine kinase domain (Sakai et al., 1995; Nakamura et al., 1996) . We hypothesized that the TEL PNT domain, when fused to the JAK2 tyrosine kinase domain, might act as a dimerization interface leading to activation of the fused tyrosine kinase as demonstrated for TEL/PDGFRβ and TEL/ABL (Carroll et al., 1996; Jousset et al., 1997) . A chimeric cDNA construct containing the sequence encoding for the TEL PNT domain (exon 1-5) fused to the murine JAK2-kinase domain (JH1) was prepared ( Figure 1 ). The protein encoded by this fusion gene was tyrosine phosphorylated and localized to the cytoplasm when overexpressed in COS-7 cells (Figure 2 ). These data suggest that, like other TEL-tyrosine kinase fusions, the TEL PNT domain acts as a self-association interface leading to constitutive activation of the JAK2-kinase domain. The TEL/JAK2 fusion protein was tested for its ability to confer factor-independent growth to hematopoietic cells. Three cDNA constructs were prepared in the retroviral expression vector MSCVneo: hTEL/mJAK2, hTEL∆PNT/mJAK2 lacking the TEL PNT domain, and hTEL/mJAK2-KI containing two point mutations in the type VIII kinase motif leading to a kinase deficiency (Zhuang et al., 1994; Carroll et al., 1996) . Murine hematopoietic Ba/F3 cells that are dependent on interleukin-3 (IL-3) for growth were infected with hTEL/ mJAK2, hTEL∆PNT/mJAK2 and hTEL/mJAK2-KI. After 48 h the cells were divided. Half were selected for G418 resistance and half were washed free of IL-3 and replated in growth medium alone. In four independent experiments, IL-3-independent cells infected with hTEL/mJAK2 were obtained after 2-4 days. No IL-3-independent cells were obtained when Ba/F3 cells were infected with hTEL∆PNT/ mJAK2 and hTEL/mJAK2-KI or the vector alone ( Figure  3A ). Immunoprecipitation with an antibody against the murine JAK2-JH1 domain followed by Western blotting confirmed that the hTEL/mJAK2 fusion protein and both mutants were highly expressed ( Figure 3B ). To determine whether the hTEL/mJAK2 fusion protein was constitutively tyrosine phosphorylated, blots of anti-mJAK2 immunoprecipitates were probed using an anti-phosphotyrosine antibody (4G10). The hTEL/mJAK2 fusion gene product was tyrosine phosphorylated whereas no tyrosine phosphorylation was seen in cells expressing the TEL/ JAK2 mutants or the MSCVneo vector ( Figure 3B ). Similar results were obtained when the interleukin-7 (IL-7)-dependent murine hematopoietic cell line IXN/2B was infected with hTEL/mJAK2 (Park et al., 1990 ) (data not shown). These results demonstrate that, like other TEL/ tyrosine kinase fusion proteins (TEL/PDGFβR, TEL/ ABL), fusion of TEL to the JAK2 kinase domain trans- (Golub et al., 1994) ; mJAK2, accession No. L16956 (Silvennoinen et al., 1993) , hJak2 accession No. AF005216 (Peeters et al., 1997b) .
forms hematopoietic cells, and that transformation is dependent on the TEL PNT domain as well as an active JAK2 tyrosine kinase domain.
Three TEL/JAK2 fusion variants associated with different human leukemia phenotypes transform hematopoietic cells to factor independence Three different human TEL/JAK2 fusions variants resulting from t(9;12) (p24;p13) have been reported in association with three different leukemia phenotypes (Figure 1 ). To test the transforming properties of these TEL/JAK2 fusion variants, cDNA constructs were subcloned into MSCV-neo and Ba/F3 cells were infected. As for the chimeric human-mouse TEL/JAK2 construct, all three TEL/JAK2 variants associated with human leukemia transformed Ba/F3 cells to factor independence ( Figure  3C ). In addition, all three fusion proteins were expressed at high levels and constitutively tyrosine-phosphorylated as assessed by immunoprecipitation and Western blotting ( Figure 3D ). In some experiments a low level of tyrosine phosphorylated endogenous JAK2 was observed, but was not reproducible. These results show that, independent of the presence of all or part of the JAK2 JH2 domain, all three human TEL/JAK2 fusion variants are constitutively tyrosine-phosphorylated and able to transform hematopoietic cells to growth factor independence.
All three human TEL/JAK2 fusion variants induce tyrosine phosphorylation and DNA-binding activity of STAT 5 Although STAT proteins are targets for phosphorylation by endogenous JAK2, the TEL/JAK2 fusion protein, containing only the JH1-kinase domain and lacking the domains involved in receptor association, may lack specificity for STAT proteins. Activation of STATs was analyzed in Ba/F3 cells transformed to factor-independent growth by TEL/JAK2 fusion proteins. As shown in Figure 4A , all STATs are expressed in hTEL/mJAK2-transformed cells as well as wild-type parental Ba/F3 cells from low (STAT 2, 4) to high levels (STAT 1, 3, 5, 6) . An unexplained decreased level of STAT 6 expressed in hTEL/ mJAK2 transformed Ba/F3 cells was observed in several experiments. Immunoprecipitation with anti-STAT antibodies, followed by anti-phosphotyrosine (4G10) blotting,
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showed tyrosine phosphorylation of STAT 5 ( Figure 4B ). Low levels of STAT 1 and 3 phosphorylation were observed after prolonged exposure (data not shown). Similar to the hTEL/mJAK2 chimeric fusion, increased phosphorylation of STAT 5 was detected in Ba/F3 cells transformed with all three human TEL/JAK2 fusion variants ( Figure 5A ). Phosphorylated STAT 1 could only be detected with anti-phospho-STAT 1 antibodies but not with anti-phosphotyrosine antibodies, suggesting low levels of tyrosine phosphorylation of STAT 1.
Induction of STAT DNA-binding activity by TEL/JAK2 fusion proteins was assessed by electrophoretic mobility shift assays (EMSA) using a γ-activated-sequence (GAS) oligoprobe derived from the FcγRI promoter as previously described (Ilaria et al., 1996) . Nuclear extracts of Ba/F3 cells expressing BCR/ABL and TEL/JAK2 demonstrated high levels of constitutive GAS DNA-binding activity which was impaired by addition of free phosphotyrosine, and eliminated by a cold competitor GAS oligonucleotide (Ilaria et al., 1996 ; data not shown). To identify the STATs responsible for the GAS-binding activity, specific anti-STAT antibodies were used to supershift the DNA-protein complexes. As demonstrated in Figure 5B , incubation of nuclear extracts from Ba/F3 cells transformed by the human-mouse and the three human TEL/JAK2 fusion variants with anti-STAT 5 antibody resulted in a complete supershift of the GAS DNA-binding activity. Antibodies to STAT 1 resulted in a small decrease in GAS DNAbinding activity. No decrease in GAS DNA-binding, or supershifting was observed when the extracts were incubated with anti-STAT 3 or anti-STAT 6 antibodies (data not shown). These results demonstrate prominent activation of STAT 5 DNA-binding activity in TEL/ JAK2-transformed cells, with less activation of STAT 1, consistent with the tyrosine phosphorylation profile.
Rapid development of a mixed myelo-and lymphoproliferative disease in mice transplanted with TEL/JAK2 retrovirally transduced bone marrow To assess the consequences of ectopic expression of a gene involved in normal or malignant hematopoiesis in vivo, lethally irradiated mice were reconstituted with bone marrow infected with retroviral expression vectors containing the gene of interest (Johnson et al., 1989; Daley et al., 1990; Elefanty et al., 1990 Elefanty et al., , 1992 Hawely et al., 1992 , Gishizky et al., 1993 Kuefer et al., 1997) . To characterize the transforming potential of TEL/JAK2 in an animal model, murine bone marrow cells were infected with the retroviral expression vector MSCV containing the cDNA coding for the in vitro-characterized chimeric human-mouse TEL/JAK2 and the human counterpart [TEL/JAK2 (5-19)] fusion gene. MSCV has been previously used to induce transformation of either lymphoid or myeloid lineage cells (Hawely et al., 1992; Lavau et al., 1997) . To increase the efficiency of the retroviral gene transfer, infection of primary murine bone marrow cells was performed on fibronectin-fragment (CH-296, Retronectin™) coated plates (Hanenberg et al., 1996; Kuefer et al., 1997) . Forty mice were transplanted with 5324 MSCV-TEL/JAK2 [30 hTEL/mJAK2; 10 TEL/JAK2 (5-19)] infected bone marrow in three separate experiments with independently prepared viral supernatants. All animals died of disease within 4-10 weeks post transplant as shown in a Kaplan-Meier survival plot ( Figure 6 ).
Pathological examination was performed on 37 animals. Seven out of seven animals from the first transplant series (1.1-1.10) developed a myeloproliferative disorder, with enlarged spleen and expansion of the red pulp by maturing myeloid elements; elevated white blood cells (WBC: 9-180ϫ10 6 /ml) with mature and immature myeloid progenitors seen in blood smears, and variable degrees of extramedullary hematopoiesis involving mostly the liver, as well as lymph nodes and adrenal medulla (Table I and Figure 7A -D). The lungs showed areas of chronic hemorrhage accompanied by aggregates of macrophages ( Figure 7G ). In three of these seven animals with the myeloproliferative disorder, enlarged lymph nodes containing a high-grade lymphoid neoplasm were found in the abdomen as well as in cervical lymph nodes. All eight animals from the second transplant series (2.2-2.10) showed extensive involvement of a high-grade lymphoid neoplasm ( Figure 7E ) concomitant with signs of myeloproliferative disease at variable levels (WBC: 5-175ϫ 10 6 /ml). In one animal (2.8), immature lymphoid cells were also observed in the blood smear. In addition, lymphoid blasts were mixed with maturing myeloid elements on some tumor specimens from the same animal ( Figure 7E-F) . The lymphoproliferation was locally destructive, infiltrating and replacing normal pancreas, kidney and liver ( Figure 8H ).
To confirm the presence of MSCV-TEL/JAK2 provirus in affected tissues, DNA was isolated from various organs and digested with KpnI to release the entire 5.5 kb provirus. Southern blot analysis of DNA from animal 2.5 using a Neo probe showed provirus in blood, bone marrow, spleen, thymus and lymph nodes as well as lungs and liver, reflecting the pattern of widespread disease seen on histopathological examination ( Figure 8A ). This blot is representative of DNA analysis of 10 TEL/JAK2 transplanted animals. The presence of tumor masses containing lymphoid blasts as well as myeloid precursors raised the question whether these masses are collision tumors comprised of a mixture of myeloid and lymphoid clones, or a single clone with bi-phenotypic differentiation potential. To address clonality of the neoplastic cells, DNA was digested with EcoRI, which has a single site within in the MSCVneo-TEL/JAK2 provirus DNA. Southern blot analysis showed the presence of several distinct bands in all the organs of mouse 2.5 (not shown). Mice of the second BMT (2.2, 2.4, 2.5) all showed enlarged spleens with an increase of myeloid cells and enlarged lymph nodes that contained mostly lymphoid blasts with some masses containing myeloid precursors. Therefore, provirus integration was analyzed in spleen and lymph nodes from these animals. As demonstrated in Figure 8B , several distinct bands were observed in all samples analyzed. The different provirus integration pattern with partial overlap in spleen versus lymph nodes supports the presence of a mixture of myeloid and lymphoid clones responsible for the disease. In addition, the variation in intensity of the observed bands compared with the DL-1 cell line containing a single copy of BCR/ABL-neo provirus Fig. 3 . Transformation of Ba/F3 cells to IL-3-independent growth by hTEL/mJAK2 is dependent on the hTEL PNT domain and an active mJAK2 JH1 tyrosine kinase domain. All three different human TEL/JAK2 fusion protein variants (4-17, 5-12, 5-19) transform Ba/F3 cells to IL-3 independent growth. (A) Ba/F3 cells (1ϫ10 6 ) were infected with retroviral expression vectors (MSCVneo) encoding either wild-type hTEL/JAK2; a mutant lacking the TEL PNT domain (hTEL∆PNT/mJAK2); or a mutant containing an inactive mJAK2 JH1-kinase domain (hTEL/mJAK2-KI). After 48 h, the cells transduced with hTEL/mJAK2 were washed free of IL-3, and cultivated until the cells reached logarithmic growth. Cells transduced with the mutants were selected in medium containing IL-3 and G-418. After selection, the cells were washed free of IL-3, plated in duplicate to 1ϫ10 5 cells, and counted daily. The figure represents three independent experiments. (B) All transduced constructs are expressed in Ba/F3 cells but only the wild-type hTEL/mJAK2 fusion protein is tyrosine phosphorylated. Total cell lysates were prepared using lysis buffer containing 1% Triton X-100. Lysates (1 mg input protein) were immunoprecipitated with a rabbit anti-JAK2(JH1) antibody, separated on an 8% SDS-PAGE, blotted and probed with an anti-phosphotyrosine antibody (4G10). The blot was then stripped and reprobed with the rabbit anti-JAK2(JH1) antibody initially used for IP. TEL fusion proteins appear as doublets due to two closely spaced start sites in the TEL cDNA. All three human TEL/JAK2 fusion variants transform Ba/F3 cells to factor-independent growth (C). The fusion proteins are expressed and tyrosine phosphorylated (D). Experiments shown in (C) and (D) were performed exactly as described in (A) and (B), respectively.
( Figure 8B ) further supports oligoclonality of the disease, rather than a single clone with potential for myeloid and lymphoid maturation (Daley et al., 1990) .
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Flow-cytometric immunophenotypic analysis was performed on single-cell suspensions from the spleens of affected animals. In some animals, where histopathology revealed predominantly myeloid expansion (e.g. animal 1.2; Figure 9A ), the spleen contained a large number of Gr-1ϩ and Mac-1ϩ granulocytes (45% compared with Ͻ5% in spleens from normal BALB/c mice). In mice in which lymphoproliferative disease predominated (e.g. animal 2.4), the number of Gr-1ϩ and Mac-1ϩ cells was not increased. Most of the lymphoid cells expressed intermediate to high levels of CD3, indicating that they were T cells. Only a small percentage of the splenocytes displayed an immunophenotype typical of mature splenic B lymphocytes (B220ϩ and CD3-). Many of the CD3ϩ cells expressed B220 at levels below that seen on normal B cells. Analysis of CD4 and CD8 staining by the same splenocytes demonstrated a mixture of CD4ϩ, CD8ϩ, and CD4ϩCD8ϩ T cells. T cells double positive for CD4 and CD8 represent immature T cells normally confined to the thymus; their presence in the spleens of these mice is consistent with a neoplastic proliferation of T cells.
To identify cells containing the retroviral expression vector, 10 mice were transplanted with a TEL/JAK2 retroviral expression construct variant (MSCV-TEL/JAK2-IRES EGFP) that contains an expression cassette for the enhanced green fluorescent protein (EGFP) driven from an internal ribosome entry site (IRES) derived from mRNA of the encephalomyocarditis virus (ECMV) (Kim et al., 1992; Gurtu et al., 1996; Persons et al., 1997) . Fluorescence of the abnormal cells was examined to identify cells expressing the retroviral construct. A distinct population of cells with EGFP fluorescence ( Figure 9B ) was seen in the lymph nodes of a mouse in which the EGFP-containing construct was used (animal 3.18 with lymphadenopathy and 18% EGFPϩ cells). In contrast, cells with this level of fluorescence were essentially absent from the lymph node of animal 2.4 (which also had lymphadenopathy, but 5326 did not have the IRES-EGFP cassette as part of the retroviral construct). Similarly, 9% of the spleen cells from animal 3.1 displayed sufficient levels of EGFP fluorescence to define a subset of cells that was essentially absent from the spleen of animal 1.2 which also had myeloproliferative disease. Using regions consisting only of cells with clear EGFP fluorescence, we used immunophenotyping to show that the EGFPϩ cells in animal 3.18 were nearly all T lymphocytes positive for CD8 that included a subset with a high level of CD3. The same gating strategy was used to show that 77% of the EGFPϩ spleen cells in the spleen of animal 3.1 expressed the granulocyte marker Gr-1 ( Figure 9C ). TEL/JAK2 protein expression was further confirmed by immunohistochemical analysis of tumor tissue as well as of total protein lysates from lymph nodes, bone marrow and spleens of animals with disease (data not shown).
In control BMT experiments, 10 animals each were transplanted with either the MSCVneo-hTEL-∆PNT/ mJAK2 or MSCVneo-hTEL/mJAK2-KI constructs which do not transform cell lines to factor-independent growth (Figure 2) . None of these 20 animals developed any signs of disease post transplant (Ͼ20 weeks), and two animals that were analyzed by histopathology showed no microscopic evidence of disease ( Figure 6 , Table I ; data not shown).
Taken together, these results show that a TEL/JAK2 fusion gene is capable of inducing a reproducible and rapidly fatal, oligoclonal, mixed myelo-and T-cell lymphoproliferative disorder in mice. The characteristics of the disease with the presence of a mixture of lymphoid and myeloid clones is consistent with the observed association of TEL/JAK2 fusion genes with human myeloid (e.g. No increase in phospho-STAT 1 was detected in several experiments while 4G10 probing, but seen when probed with antiphospho-STAT1. (B) Induction of STAT GAS DNA binding activity by TEL/JAK2. Nuclear extracts from parental, hTEL/mJAK2 and TEL/JAK2 (4-17, 5-12 and 5-19) Ba/F3 cells were analyzed by EMSA using 32 P-labeled FcγRI-derived GAS probe. No baseline GAS DNA-binding was observed in nuclear extracts from parental Ba/F3 growing in the absence of IL-3 for 12 h. WEHI (cellular IL-3 source) stimulated Ba/F3 cells produced a completely supershifted complex when anti-STAT5 antibodies were added. Adding of 10-100ϫ cold competitor GAS probe fully abrogated the complex (data not shown). Baseline GAS DNA-binding complexes from parental Ba/F3 cells (an unexplained higher molecular weight band was observed in some experiments) and TEL/JAK2 transformed cells were completely supershifted when anti-STAT 5 antibodies were added to the reaction. Adding of anti-STAT 1 antibodies showed a decrease in baseline GAS DNA-binding but no significant supershift. Adding of anti-STAT 2, STAT 3 or STAT 6 showed no effect on GAS DNA complexes (data not shown).
CML-like disease) and lymphoid (e.g. B-ALL and T-ALL) leukemias.
Discussion
The recent characterization of the breakpoint of the translocation (9;12) (p24;p13) identified three different TEL/ JAK2 fusion variants, each of which is associated with a different leukemic phenotype (Lachronique et al., 1997; Peeters et al., 1997b ). Here we demonstrate the trans-5327 Fig. 6 . Comparative survival analysis of TEL/JAK2 bone marrow transplanted mice (Kaplan-Meier). Mice transplanted with bone marrow transduced with hTEL/mJAK2 (n ϭ 30), or hTEL/hJAK2 (5-19) (n ϭ 10) die of disease within 10 weeks after transplant. None of the mice transplanted with bone marrow transduced with the nontransforming mutants (hTEL∆PNT/mJAK2, n ϭ 10; hTEL/mJAK2-KI, n ϭ 10) died of disease after 30 weeks post-transplant.
forming properties of TEL/JAK2 fusion proteins in vitro and in vivo. Murine hematopoietic cells with myeloid and lymphoid phenotypes (Ba/F3, Ixn/2B) are transformed to factor-independent growth by expression of a chimeric fusion gene containing exon 1-5 of human TEL fused to the murine JH1-JAK2 kinase domain. Mutants either lacking the TEL PNT domain or containing an inactivating mutation in the JAK2-kinase domain demonstrate that transformation is dependent on the TEL PNT domain as well as an active JAK2-kinase domain (Lachronique et al., 1997) . These data, together with the previous characterization of other transforming TEL-tyrosine kinase fusions (TEL-PDGFRβ, TEL-ABL), further emphasize the importance of the TEL PNT domain as a self-association motif leading to constitutive activation of the tyrosine kinase partner (Carroll et al., 1996; Golub et al., 1996; Jousset et al., 1997) . There is increasing evidence that ligand-independent oligomerization, or activation through point mutations, is a general mechanism for oncogenic activation of receptor and nonreceptor tyrosine kinases in leukemias as well as in solid tumors. In addition to the TEL PNT domain, the BCR coiled-coil domain (BCR/ ABL), the leucine-zipper (TPR-MET, TPR-TRK, HIP-PDGFRβ) and the zinc-finger motifs (FGR1-ZNF198) may serve as dimerization/oligomerization interfaces (Mc Whirther and Wang, 1991; Rodrigues and Park, 1994; Ross et al., 1998; Xiao et al., 1998) .
Comparison of the in vitro transformation properties of the TEL/JAK2 fusion variants showed no difference in induction or kinetics of factor-independent growth in Ba/ F3 cells. In contrast with the TEL/JAK2 (5-19) fusion, which contains only the JAK2 JH1-kinase domain, TEL/ JAK2 (5-12) and TEL/JAK2 (4-17) fusion variants contain all of, and part of the JH2 pseudo-kinase domain, respectively (Figure 1 ). The role of the JH2 domain, which has similarities to known tyrosine kinase domains but does not contain certain amino acid residues that are required for catalytic activity, has not been characterized in detail. Luo et al. (1997) demonstrated hyperactivation of Drosophila and mammalian JAK-STAT pathway by a mutation in the Jak JH2-kinase domain. However, by analysis of deletion mutants, these authors suggest that at least in Drosophila, the JH2 domain may not serve solely as a negative regulatory element (Luo et al., 1997) . Additional evidence for functional importance of the JAK2 JH2 domain has been demonstrated by expression of CD16 (dimerization motif)-CD7-JAK2 chimeric proteins in factor-dependent Ba/F3 cells. Stably transfected clones with a CD16-CD7-JAK2 JH1 domain induced bcl-2 and pim-1 gene expression and delayed cell death whereas a fusion including the JAK2 JH2 and JH1 did not, although 5328 both proteins were constitutively phosphorylated (Sakai and Kraft, 1997) . However, there were no detectable differences in in vitro transformation ability of the three TEL/JAK2 variants, suggesting that the JH2 domain does not influence transformation in this context. Ba/F3 cells transformed to factor-independent growth by TEL/JAK2 fusion variants show an increase in tyrosine phosphorylation of STAT 5. EMSA analysis shows that there is also increased STAT 5 DNA-binding activity compared with wild-type cells, and these data are similar to those reported by Lachronique et al. (1997) . Recent work in our laboratory has further demonstrated that transformation by other TEL-tyrosine kinase fusions (TEL/ PDGFRβ, TEL/ABL) is also associated with increased STAT 5 activity (M. Carroll and D.G.Gilliland, in preparation) . These findings, together with several reports that have shown activation of the JAK-STAT pathway in BCR/ ABL transformed cells, suggest that specific activation of STAT 5 is a common theme in cellular transformation by tyrosine kinase fusion proteins (Carlesso et al., 1996; Ilaria et al., 1996; Shuai et al., 1996) . STAT 5 was originally characterized as a transcription factor mediating prolactin response in mammary epithelial cells. Further studies have demonstrated activation of STAT 5 by variety of hormones and cytokines (e.g. IL-2, IL-3, IL-7, GM-CSF, EPO, TPO, EGF amongst others). Moreover, it has been demonstrated that STAT 5 activity is involved in regulation of IL-3-induced proliferation of hematopoietic cells (Mui et al., 1996) . However, a large number of studies have shown that oncogenic tyrosine kinase fusion genes may mediate their function through activation of 5329 several signaling pathways. The first and best characterized hematological tyrosine kinase fusion, BCR/ABL, associated with CML, activates multiple downstream effector molecules (Cortez et al., 1995 (Cortez et al., , 1996 . In addition to activation of the JAK-STAT pathway, BCR/ABL activates RAS and MAP kinase which appears to be required but not sufficient for cellular transformation (Goga et al., 1995; Raitano et al., 1995) . Moreover, transformation by BCR/ABL also involves PI3-kinase activation of Akt kinase as a downstream target (Skorski et al., 1997) . Based on these studies, it remains to be elucidated whether other pathways, in addition to STAT activation, are activated in TEL-tyrosine kinase mediated cell transformation. Murine primary bone marrow was infected with a retroviral expression vector containing the TEL/JAK2 (5-19) fusion gene variant and transplanted into lethally irradiated syngeneic recipients to address transformation of hematopoietic cells by TEL/JAK2 in vivo. This technique (Table I ). The cells were stained with FITC-conjugated anti-Mac-1 and biotinylated anti-Gr-1 followed by streptavidin-PE, demonstrating an expansion of Gr-1ϩ, Mac-1ϩ granulocytes in 1.2 spleen and a normal percentage of granulocytes in the 2.4 spleen. Staining of 2.4 splenocytes with FITC-conjugated anti-CD3 together with PE-conjugated anti-B220 or FITC-conjugated anti-CD4 with PEconjugated CD8α demonstrated a predominance of CD3ϩ T cells which included CD4ϩ, CD8αϩ, and CD4ϩCD8αϩ subsets). (B) Dot plots of FL-1 fluorescence versus side scatter (SSC) were analyzed for unstained lymph node cells from mouse 3.18 (MSCV-EGFP-hTEL/ hJAK2) and mouse 2.4 (MSCV-neo-hTEL/mJAK2 ), both of which had lymphoproliferative disease. A population of cells with increased FL-1 fluorescence representing EGFP expression was identified only in cells from mouse 3.18. The cells in this region (18% of total cells) were further analyzed by staining with PE-conjugated anti-CD8α and biotinconjugated anti-CD3 followed by streptavidin-Tricolor (detected in FL3 channel) revealing expression of CD8α by almost all of the EGFPϩ cells and CD3 by a subset of these CD8αϩ cells. (C) A similar method was used to study spleen cells from mice with myeloproliferative disease. Cells in the spleen of mouse 3.1 (MSCV-EGFP-hTEL/hJAK2) displayed EGFP expression which was not seen in spleen cells from mouse 1.2 (MSCV-neo-hTLEL/mJAK2). Cells from mouse 3.1 that were positive for EGFP expression, 77% were positive for Gr-1 by staining with biotinylated anti-Gr-1 followed by strepatavidin-PE.
was first used to characterize the BCR/ABL fusion gene and has become an important approach for in vivo characterization of oncogenic fusion genes, as well as regulatory genes important in hematopoiesis (Elefanty et al., 1990 (Elefanty et al., , 1992 Daley et al., 1990; Hawely et al., 1992) . TEL/JAK2-transplanted animals rapidly develop a fatal oligoclonal 5330 mixed myelo-and T-cell lymphoproliferative disease. This finding is similar to other oncogenic fusion-gene murine transplant models, as rapidly fatal oligoclonal disease has also been observed in animals transplanted with BCR/ ABL-infected marrow cells (Gishizky et al., 1993) . In other studies, involvement of several lineages has also been described, but multiple phenotypically distinct tumors in the same animal have been traced back to a single infected multipotent precursor cell in most cases. (Elephanty et al., 1990 (Elephanty et al., , 1992 . In certain respects, the disease generated by the TEL/JAK2 transplant model is similar to the phenotype observed after transplant of bone marrow infected with a retrovirus that contains genes coding for growth factors associated with the myeloid lineage; overexpression of GM-CSF, G-CSF, as well as IL-3, induce a oligoclonal myeloproliferative syndrome, with a fatal outcome in the case of IL-3 and GM-CSF (Chang et al., 1989a,b; Johnson et al., 1989) . These similarities might be explained by the fact that activation of the JAK2 kinase has been shown to play an important role in signaling of these cytokines (Silvennoinen et al., 1993; Ihle et al., 1995) . The early onset myelo-and lymphoproliferative syndrome in TEL/JAK2-transplanted mice suggests that the disorder may originate from more differentiated progenitor cells with limited replication capacity that have undergone oligoclonal expansion. However, the use of Retronectin TM in these experiments may also influence the development of oligoclonal disease. Retronectin™ is comprised of specific proteolytic fragments of fibronectin, and is a potent enhancer of retrovirally mediated gene transfer in long-term repopulating murine hematopoietic cells and in human CD34ϩ cells (Hanenberg et al., 1996) . Clonal lymphoid disease has been observed in mice transplanted with bone marrow infected with low titer of MSCV retrovirus encoding for NPM-ALK, a tyrosine kinase fusion gene associated with human lymphomas, using Retronectin™ as an enhancing agent for gene transfer (Kuefer et al., 1997) . Therefore, it is also possible that the use of high-titer viral supernatants together with RetronectinTM as a gene transfer enhancing agent may promote oligoclonal disease. Experiments with titration of the viral supernatants and variation of transplanted cell numbers will be required to address this question.
Development of T-cell lymphoproliferative disease in mice transplanted with TEL/JAK2 (5-19), originally cloned from a patient with T-ALL is of interest, as JAK1 and JAK3 (but not JAK2) have been shown to be critical for mediation of a proliferative signal by IL-2 in T cells (Nelson et al., 1994) . However, activation of JAK1 and JAK3 leads to tyrosine phosphorylation of STAT 5, as well as to a lesser extent STAT 1 and STAT 3 (Gilmour et al., 1995; Johnston et al., 1995) . These data would suggest that activation of STAT 5 may induce T-cell expansion in TEL/JAK2 bone marrow transplants. Additional bone marrow transplant experiments with the other TEL/JAK2 fusion variants, TEL/JAK2 (4-17) and TEL/ JAK2 (5-12) (associated with B-ALL and atypical CML, respectively) will be required to determine whether the phenotype associations seen in humans can be recapitulated in the animal model. This animal model of TEL/JAK2-induced hematopoietic malignancy offers a rapid and reliable tool to test the requirement for specific signaling molecules in transformation by TEL/JAK2 and other TEL/tyrosine fusions. It also provides a model system to test new therapeutic approaches, such as JAK-specific tyrosine inhibitors (e.g. tyrphostin AG 490; Meydan et al., 1996) , naturally occurring dominant negative variants of STAT 5 (Wang et al., 1996; Azam et al., 1997) , STAT decoy oligonucleotides (Boccaccio et al., 1998) , and endogenous JAK-STAT inhibitors (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . Characterization of transformation by TEL/ JAK2 fusion genes provides further insight into the role of the JAK-STAT pathway in human leukemogenesis.
Materials and methods

Cell lines
Murine Ba/F3 cells (a gift from A.D'Andrea, Dana Farber Cancer Institute, Boston, MA) were maintained in RPMI-1640 medium with 10% fetal bovine serum (FBS) and 0.5-1 ng/ml of recombinant IL-3 (R&D Systems, Minneapolis, MN) in a 5% CO 2 incubator at 37°C. Murine IXN/2B cells (Park et al., 1990 ; kind gift from Immunex, Seattle, WA) were kept in IL-7-containing IMDM medium. COS-7 and 293-T cells were maintained in DMEM with 10% FBS.
DNA constructs and retroviral vectors
The chimeric hTEL/mJAK2 cDNA was constructed by PCR by linking TEL (nt 1-1033) to murine JAK2-JH1 (nt 2575 (nt -3629, Silvenoinen et al., 1993 using the unique AvrII site between mJAK2 JH2 and JH1 domains, sequenced and expressed by in vitro transcription/translation using a rabbit reticulocyte lysate kit (TNT system; Promega, Madison, WI). For expression in COS-7 cells, the cDNA was subcloned into HATELpcDNA3 (Carroll et al., 1996) . The hTEL∆PNT/mJAK2 cDNA lacking the TEL PNT domain was generated by cutting within the TEL cDNA at BspMI and EcoNI sites, blunting with mung bean nuclease and religating, leading to deletion of nucleotides 195-348 of the TEL gene (Carroll et al., 1996) . The hTEL/kinase deficient mJAK2 fusion mutant was generated by mutation of two conserved amino acids (Trp→Gly; Glu→Ala) in the type VIII kinase motif using site-directed mutagenesis (Site Directed Mutagenesis Kit, Stratagene, La Jolla, CA) as described previously (Zhuang et al., 1994) . Human TEL/JAK2 (TEL exon 5-JAK2 exon 19) was constructed similarly to hTEL/mJAK2 using a unique StuI site near the breakpoint into the human JAK2 cDNA (Peeters et al., 1997b; Dalal et al., 1998) . The human TEL/JAK2 (TEL exon 4-JAK2 exon 17) and (TEL exon 5 -JAK2 exon 12) cDNAs were subcloned from pGreenlantern into retroviral expression vectors using standard techniques (Figure 1 ).
Retrovirus production and transfer into hematopoietic cell lines and primary murine bone marrow
For gene transfer into Ba/F3 cells and primary murine bone marrow, cDNA constructs were subcloned into the retroviral expression vector murine stem cell virus (MSCV) known to yield high virus titer capable of efficient transduction and expression of genes in hematopoietic cells (Hawely et al., 1994; Lavau et al., 1997) . In some experiments a variant (MSCV version 2.2, kindly provided by W.Pear, University of Pennsylvania, PA) containing an IRES (internal ribosomal entry site)-EGFP expression cassette was used (Parsons et al., 1997) . Retroviral stocks were generated by transient cotransfection of 293-T cells with the respective MSCV construct together with a packaging construct (pIK6, Cell Genesys Inc., Foster City, CA) providing sequences necessary for retrovirus production (Finer et al., 1994) . Forty-eight hours posttransfection, virus containing supernatant was harvested, filter sterilized (0.45 µm) and kept at -70°C. For transformation assays as well as estimation of the viral titer, Ba/F3 cells (0.5-1.0ϫ10 6 ) were infected with retrovirus (MSCV-EGFP) containing supernatant with 10 µg/ml polybrene. After 48 h, the percentage of infected cells was determined by counting EGFP positive cells (fluorescent microscope or flow cytometry); estimated viral titers of ജ5ϫ10 5 ml were obtained. For in vitro transformation assays, the cells were split, washed twice in phosphatebuffered saline (PBS) and selected in G-418 (1 mg/ml) or put into IL-3-free medium. For infection of primary murine bone marrow 6-8 week old BALB/cBvJ mice (Taconic, Germantown, NY) were primed with 150 mg/kg 5-Fluorouracil (5-FU, Sigma, St Louis, MO) administrated 5331 intraperitoneally beginning 6 days prior to harvest. Two days before transplantation, male donor mice were sacrificed by CO 2 asphyxiation followed by cervical dislocation, the femurs and tibias removed and the bone marrow flushed with medium using sterile techniques. After counting (3-5ϫ10 6 cells/mouse) the cells were incubated for 48 h in a cocktail with recombinant murine IL-3 (6 U/ml; Genzyme, Cambridge, MA), recombinant murine stem cell factor (SCF, 5 U/ml; Genzyme, Cambridge, MA), recombinant murine Interleukin-6 (IL-6, 10 000 U/ml) (Peprotech), 20% FBS, 100 U/ml penicillin/streptomycin (Gibco-BRL, Gaithersburg, MD) in RPMI 1640 medium (10 ml) with 1 ml viral supernatant in Retronectin™ (Tanaka-Shuzo, Japan)-coated Petri dishes (Hanenberg et al., 1996) . After 24 h viral soup was added again and the cells were incubated for additional 24 h. The cells were then harvested, washed and injected (0.5-1ϫ10 6 in 500 µl HBSS) into the tail vein of previously lethally-irradiated (2ϫ450cGy) female syngeneic recipient mice. The recipient mice were maintained in microisolator cages with acidified water and autoclaved chow at the animal facility of Harvard Medical School, Boston, MA.
Southern blot analysis
Genomic DNA was isolated form various tissues using a PUREGENE DNA isolation kit (Gentra Systems, Minneapolis, MN) followed by a single phenol-chloroform extraction. DNA (10 µg) was digested with restriction enzymes (10-20 U/µg DNA, Boehringer Mannheim), sizeseparated on a 1% TBE-agarose gel and blotted to a Nylon membrane (Hybond Nϩ, Amersham, Arlington Heights, IL) by alkaline transfer. The membranes were then hybridized to [ 32 P]dCTP-labeled DNA probes (1-2ϫ10 6 c.p.m./ml) in a aqueous hybridization buffer (5ϫ SSC, 10% Dextran sulfate, 5ϫ Denhardt's, 0.1% SDS) at 65°C.
Protein analysis
Parental cells and cells expressing the TEL/JAK2 fusion proteins were lysed in 1% Triton X-100 lysis buffer with protease inhibitor cocktail tablets (Complete Mini™ Boehringer Mannheim), 1 mM sodium vanadate, 10 mM sodium fluoride, 10 mM EDTA, and quantified by the Bradford colorimetric method. Lysates (1 mg input protein) were used for immunoprecipitation with 1 µl of rabbit polyclonal anti-JAK2 antibody directed against the C-terminus (kindly provided by A.Ziemiecki, University of Berne, Switzerland) or 3 µl of anti-STAT antibodies (Trans Cruz anti-STAT 1, STAT 2, STAT 3, STAT 4, STAT 5b, STAT 6; Santa Cruz, CA) at 4°C for 1-12 h. The protein was precipitated with Staph-A or protein-G Sepharose (1:3), washed 3 times with 1% Triton X-100 lysis buffer, separated by PAGE and transferred to a nylon membrane (Millipore) or nitrocellulose membrane (Corning). Immunoblotting was performed with 4G10 (UBI), rabbit anti-mJak2, rabbit anti-TEL-PNT domain, anti-phospho-STAT [PS-1 antibody which detects tyrosine phosphorylated STAT 1 (α and β isoforms) and STAT 5; kindly provided by D.Frank, Dana Farber Cancer Institute, Boston, MA] and anti-STAT antibodies at a dilution of 1:1000-1:2000 in TBS-T for 1 h (Frank et al., 1997) . Blots were washed four times in TBS-T, incubated with HRP-conjugated anti-mouse or anti-rabbit antibodies for 30 min and visualized with ECL reagent (Amersham, Arlington Heights, IL). EMSAs were performed as described previously (Ilaria et al., 1996) . In brief, nuclear extracts (6 µg) from parental and cells expressing TEL/ JAK2 fusion proteins are incubated (20 min) with a 32 P-labeled and purified double-stranded oligonucleotide probe recognized by activated STAT protein complexes (GAS based on the FcγRI gene promoter). For supershift analysis, anti-STAT antibodies (Santa Cruz) were added. The DNA-protein complexes were resolved on 4% TAE-polyacrylamide gels and detected by autoradiography. To localize hemagglutinin (HA)-tagged hTEL/mJAK2 in COS-7 cells, 48 h after transfection the cells were fixed in 3% formaldehyde and blocked with 1% dried milk solution in PBS/0.1% Triton X-100 and probed with an anti-HA antiserum (Boehringer Mannheim) followed by an FITC-labeled secondary antibody, briefly stained with HOECHST 33258, and analyzed with an immunofluorescence microscope.
Histopathologic and immunohistochemical analysis of murine tissues
Murine tissues were fixed for 24 h in 10% neutral buffered formalin and embedded in paraffin. Femurs were subjected to an additional decalcification step in RDO (Apex Engineering Products, Plainfield, IL) for 4 h prior to processing. Sections (3 µm) were deparaffinized and stained with hematoxylin and eosin.
Flow-cytometric analysis
Single cell suspensions of bone marrow, spleen and lymph nodes were prepared. Red blood cells were lysed in ammonium chloride solution (150 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA, pH 7.4) for 5 min at room temperature. The cells were washed in PBS with 0.1% NaN 3 and 0.1% BSA (staining buffer). To block nonspecific Fc receptormediated binding, the cells were preincubated with supernatant from the 2.4G2 hybridoma line (anti-CD16/CD32; cell line obtained from American Type Culture Collection, Rockville, MD) for 20 min on ice. Aliquots of 0.5-1.0ϫ10 6 cells were then stained for 20 min on ice with monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), or biotin. The antibodies used in these experiments included reagents specific for: B220 (CD45R), CD3, CD4, CD8α, Mac-1(CD11b) and Gr-1 (all antibodies purchased from PharMingen, San Diego, CA). The binding of biotinylated primary antibodies was detected using PE-conjugated streptavidin (Immunotech, Westbrook, ME) or Tricolor-conjugated streptavidin (Caltag, South San Francisco, CA). Cells were washed once in staining buffer and multicolor flowcytometric analysis was done with a FACScan (Becton-Dickinson). A minimum of 10 000 events were acquired and the data was analyzed using CellQuest software (Version 3.1). The results are presented as dot plots showing FITC and PE fluorescence signals of viable cells gated on the basis of forward and side scatter signals. In mice transplanted with bone marrow transduced with an EGFP-containing retroviral construct, dot plots of FL-1 fluorescence versus side-scatter were used to identify the EGFP-positive cells. A region encompassing only the cells expressing EGFP was defined and used to gate the cells for analysis of additional markers (CD3 and CD8α for lymphoid cells and Gr-1 for granulocytes).
